StockData
Evotec SE logo

Evotec SE (EVO) stock

EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 4/30
$1.46−0.02 (-1.35%)

Close on Nov 18, 2026Market cap $519.11MP/E –Yield –

Evotec free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -€81.72M. The highest annual figure on record is €24.46M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€81.72M–
FY2024Dec 31, 2024-€99.25M–
FY2023Dec 31, 2023-€176.88M-823.2%
FY2022Dec 31, 2022€24.46M+219.4%
FY2021Dec 31, 2021€7.66M–
FY2020Dec 31, 2020-€54.35M-598.9%
FY2019Dec 31, 2019€10.89M–

More Evotec figures

See a number that looks wrong?